Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8376481,flow-rate,"The drugs and metabolites are eluted with a mobile phase containing potassium phosphate buffer-acetonitrile-methanol (110:50:30, v/v/v) at a flow-rate of 0.2 ml/min.","Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),[ml] / [min],0.2,6438,DB00794,Primidone
,8376481,recovery rates,The recovery rates range from 95.12 to 104.42%.,"Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),%,95.12 to 104.42,6439,DB00794,Primidone
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,6.2,14472,DB00794,Primidone
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,83.5,14473,DB00794,Primidone
,7471611,half-life (t 1/2),"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),h,15.2,36747,DB00794,Primidone
,7471611,apparent clearance,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],35,36748,DB00794,Primidone
,7471611,t 1/2,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),h,8.3,36749,DB00794,Primidone
,7471611,clearance,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],51,36750,DB00794,Primidone
,7471611,apparent clearance,In four CT patients in whom other antiepileptics were withdrawn there was a decrease in apparent clearance (61.4 to 29.9 ml/hr/kg) no rates in the range of MT patients.,Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],61.4 to 29.9,36751,DB00794,Primidone
,10716065,Tmax,"After administration, by intraperitoneal injection (50, 100 or 200 mg/kg), primidone rapidly appeared in both serum (Tmax mean range 1.5-2.5 h) and CSF (Tmax mean range 2.0-3.5 h), suggesting ready penetration of the blood-brain-barrier.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),h,1.5-2.5,38273,DB00794,Primidone
,10716065,Tmax,"After administration, by intraperitoneal injection (50, 100 or 200 mg/kg), primidone rapidly appeared in both serum (Tmax mean range 1.5-2.5 h) and CSF (Tmax mean range 2.0-3.5 h), suggesting ready penetration of the blood-brain-barrier.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),h,2.0-3.5,38274,DB00794,Primidone
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.86,38275,DB00794,Primidone
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.97,38276,DB00794,Primidone
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.88,38277,DB00794,Primidone
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.73,38278,DB00794,Primidone
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,1.06,38279,DB00794,Primidone
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.65,38280,DB00794,Primidone
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00794,Primidone
,6403891,accumulation half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,49.7,52153,DB00794,Primidone
,6403891,time to steady state,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),d,10.4,52154,DB00794,Primidone
,6403891,elimination half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,72.2,52155,DB00794,Primidone
,7891306,recovery rates,The recovery rates were 96.8-101.8%.,Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),%,96.8-101.8,57836,DB00794,Primidone
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,1.4,57837,DB00794,Primidone
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,5.7,57838,DB00794,Primidone
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,6.6,57839,DB00794,Primidone
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],18.2,57840,DB00794,Primidone
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],8.1,57841,DB00794,Primidone
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],9.6,57842,DB00794,Primidone
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00794,Primidone
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00794,Primidone
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00794,Primidone
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00794,Primidone
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00794,Primidone
,543743,half-life,"Primidone was rapidly absorbed, so that maximal serum concentrations were reached after 2 hr, the concentration fell then with a half-life averaging 5 hr in Beagles and 10 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,5,79797,DB00794,Primidone
,543743,half-life,"Primidone was rapidly absorbed, so that maximal serum concentrations were reached after 2 hr, the concentration fell then with a half-life averaging 5 hr in Beagles and 10 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,10,79798,DB00794,Primidone
,543743,ka,"PEMA appeared in plasma with a ka of 0.003--0.005 min-1, reached maximal concentrations after about 6.5 hr in Beagles and 12 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),1/[min],0.003,79799,DB00794,Primidone
,543743,elimination half-life,The elimination half-life averaged 7.5 hr in Beagles and 14 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,7.5,79800,DB00794,Primidone
,543743,elimination half-life,The elimination half-life averaged 7.5 hr in Beagles and 14 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,14,79801,DB00794,Primidone
,543743,elimination half-life,Phenobarbital had an elimination half-life of 32 +/- 4.8 hr in Beagles and of 70 +/- 16 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,32,79802,DB00794,Primidone
,543743,elimination half-life,Phenobarbital had an elimination half-life of 32 +/- 4.8 hr in Beagles and of 70 +/- 16 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,70,79803,DB00794,Primidone
,543743,steady-state concentrations,"During continued treatment with daily doses of 30--50 mg/kg primidone, steady-state concentrations of about 15 micrograms/ml (65 nmole/ml) were reached after 6--8 days, the PEMA concentrations showed rather pronounced fluctuations around average values of 8--10 micrograms/ml (39--49 nmole/ml), whereas the concentrations of primidone mainly remained below 5 micrograms/ml (23 nmole/ml).",Pharmacokinetics of primidone and its active metabolites in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),[μg] / [ml],15,79804,DB00794,Primidone
,543743,steady-state concentrations,"During continued treatment with daily doses of 30--50 mg/kg primidone, steady-state concentrations of about 15 micrograms/ml (65 nmole/ml) were reached after 6--8 days, the PEMA concentrations showed rather pronounced fluctuations around average values of 8--10 micrograms/ml (39--49 nmole/ml), whereas the concentrations of primidone mainly remained below 5 micrograms/ml (23 nmole/ml).",Pharmacokinetics of primidone and its active metabolites in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),[nmole] / [ml],65,79805,DB00794,Primidone
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,19.4,80682,DB00794,Primidone
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,10.2,80683,DB00794,Primidone
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],24.6,80684,DB00794,Primidone
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],45.1,80685,DB00794,Primidone
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],8.2,80686,DB00794,Primidone
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],11.0,80687,DB00794,Primidone
,7377892,elimination half-life,Plasma concentrations declined with an elimination half-life of 1.5 hr.,Pharmacokinetics of carbamazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,1.5,92213,DB00794,Primidone
,7377892,half-life,"The concentrations of the epoxide remained high as long as plasma concentrations of carbamazepine were above 2--4 nmole/ml, then they fell with an average half-life of 2.2 hr.",Pharmacokinetics of carbamazepine in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,2.2,92214,DB00794,Primidone
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,70,92215,DB00794,Primidone
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,40,92216,DB00794,Primidone
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB00794,Primidone
,7084140,oral bioavailability,The oral bioavailability estimated on the basis of the recovery of unchanged drug in the urine of normal subjects was at least 80%.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),%,80,105229,DB00794,Primidone
,7084140,Half-life,Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),h,17 to 25,105230,DB00794,Primidone
,7084140,Half-life,Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),h,10 to 23,105231,DB00794,Primidone
,3504397,plasma elimination half-life (T1/2),Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,14,108309,DB00794,Primidone
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,24,108310,DB00794,Primidone
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,30,108311,DB00794,Primidone
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB00794,Primidone
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB00794,Primidone
,8738192,relative recovery,"Each chromatographic separation was completed in 14 min and the results showed a relative recovery which varied between 95.9 and 116%, a good overall precision (relative standard deviation, 7.00%) and sensitivity over a linear range of 5.00-300 ng ml-1 (R = 0.999) for AVA in plasma.",Determination of apovincaminic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738192/),%,95.9,122014,DB00794,Primidone
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB00794,Primidone
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB00794,Primidone
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB00794,Primidone
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,70,138159,DB00794,Primidone
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,85,138160,DB00794,Primidone
,21351809,elimination half-life,"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,6-10,138161,DB00794,Primidone
,21351809,time to maximum plasma concentration (C(max)),"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,4-6,138162,DB00794,Primidone
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],4.01,138163,DB00794,Primidone
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],8.68,138164,DB00794,Primidone
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],37.8,138165,DB00794,Primidone
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],89.3,138166,DB00794,Primidone
,21351809,volume of distribution,The volume of distribution in children is similar to that in adults (0.8-1.2 L/kg) and the drug binds rather poorly to plasma protein (26.2-34.8%).,Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[l] / [kg],0.8-1.2,138167,DB00794,Primidone
,8991789,half-lives,The harmonic mean half-lives of 3.8 to 4.9 h were remarkably constant across dosages and shorter than those of historical control subjects not taking enzyme-inducing AEDs suggesting that epilepsy patients not taking enzyme-inducing AEDs may require lower tiagabine.,Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991789/),h,3.8 to 4.9,138431,DB00794,Primidone
,6795343,half-life,VPA was excreted in the neonates with a mean half-life of 47 +/- 15 hr (n = 8) which is approximately 4 times the mean value found in adult epileptics.,"Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795343/),h,47,148806,DB00794,Primidone
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.77,162430,DB00794,Primidone
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.89,162431,DB00794,Primidone
,6519155,elimination half-life,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),h,18.0,165188,DB00794,Primidone
,6519155,apparent clearance,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),[ml] / [h·kg],42,165189,DB00794,Primidone
,6519155,half-life,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),h,17.0,165190,DB00794,Primidone
,6519155,clearance,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),[ml] / [h·kg],35,165191,DB00794,Primidone
,7107978,Dialysis clearance,"Dialysis clearance calculated by the instantaneous dialyzate method averaged 97.7 ml/min, which is considerably greater than the metabolic clearance of 30 ml/min for the drug.",Pharmacokinetics of primidone elimination by uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),[ml] / [min],97.7,173249,DB00794,Primidone
,7107978,metabolic clearance,"Dialysis clearance calculated by the instantaneous dialyzate method averaged 97.7 ml/min, which is considerably greater than the metabolic clearance of 30 ml/min for the drug.",Pharmacokinetics of primidone elimination by uremic patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),[ml] / [min],30,173250,DB00794,Primidone
,7107978,extraction efficiency,The extraction efficiency of the hollow-fiber dialyzers averaged 40.2 pr cent for plasma samples.,Pharmacokinetics of primidone elimination by uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),cent·pr,40.2,173251,DB00794,Primidone
,7107978,half-life,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,5.1,173252,DB00794,Primidone
,7107978,half-life,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,13.9,173253,DB00794,Primidone
,7107978,half,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,13.9,173254,DB00794,Primidone
,2291873,half-lives,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),h,12.1,212076,DB00794,Primidone
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),h,14.7,212077,DB00794,Primidone
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),[ml] / [h·kg],34.8,212078,DB00794,Primidone
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),[ml] / [h·kg],33.2,212079,DB00794,Primidone
,6851372,t1/2,"Following intravenous administration, after a very short distributive phase (t1/2 = 0.23-0.53h), the decline of the log-PEMA concentration with respect to time appeared linear.",Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851372/),h,0.23-0.53,215755,DB00794,Primidone
,6851372,terminal half-life,"The pharmacokinetic parameters, calculated according to a 1-compartment open model, showed the following values (mean +/- SD): terminal half-life, 15.7 +/- 3.4h; apparent volume of distribution, 0.69 +/- 0.10 L/kg; total serum clearance, 31.3 +/- 6.6 ml/h/kg.",Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851372/),h,15.7,215756,DB00794,Primidone
,6851372,apparent volume of distribution,"The pharmacokinetic parameters, calculated according to a 1-compartment open model, showed the following values (mean +/- SD): terminal half-life, 15.7 +/- 3.4h; apparent volume of distribution, 0.69 +/- 0.10 L/kg; total serum clearance, 31.3 +/- 6.6 ml/h/kg.",Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851372/),[l] / [kg],0.69,215757,DB00794,Primidone
,6851372,total serum clearance,"The pharmacokinetic parameters, calculated according to a 1-compartment open model, showed the following values (mean +/- SD): terminal half-life, 15.7 +/- 3.4h; apparent volume of distribution, 0.69 +/- 0.10 L/kg; total serum clearance, 31.3 +/- 6.6 ml/h/kg.",Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851372/),[ml] / [h·kg],31.3,215758,DB00794,Primidone
,6851372,oral bioavailability,"After oral administration, peak serum concentrations occurred at 0.5 to 4 hours and the oral bioavailability was 86.4 to 95.9%.",Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851372/),%,86.4 to 95.9,215759,DB00794,Primidone
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB00794,Primidone
,9578000,Css,Twenty-five patients taking phenytoin (PHT) and/ or phenobarbital (PB) and/or primidone (PRM) underwent a rapid switchover to CBZ following a 10 mg/kg single-dose kinetic study (day 1) which allowed calculation of a maintenance dose necessary to yield a mean Css of 10.2 (+/-2.2) mg/l.,Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],10.2,249787,DB00794,Primidone
,9578000,Css,"All patients completed the switchover to CBZ within a mean time period of 6 days (+/-2), reaching a mean maintenance dose of 1,639 mg/day (+/-370) which yielded a mean Css of 11.3 (+/-3.2) mg/l.",Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],11.3,249788,DB00794,Primidone
,9616196,maximal velocity Vmax,"Estimated primidone metabolism, as expressed by the maximal velocity Vmax, ranged from 0 to 0.24 mg.","Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616196/),mg,0 to 0.24,270948,DB00794,Primidone
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00794,Primidone
